InMed Pharmaceuticals Submits Clinical Trial Applications to Evaluate INM-755 (Cannabinol) Cream in a Phase 2 Trial for Epidermolysis Bullosa
28 avr. 2021 07h30 HE
|
InMed Pharmaceuticals Inc.
Filings submitted in Austria, Israel, and Serbia for a Phase 2 Clinical Trial with INM-755 creamAdditional submissions slated for France, Germany, Greece, and Italy over the next several days and...
Rapid Therapeutic Completes $14 Million Acquisition of Razor Jacket
01 déc. 2020 07h00 HE
|
Rapid Therapeutic Science Laboratories
DALLAS, Dec. 01, 2020 (GLOBE NEWSWIRE) -- Rapid Therapeutic Science Laboratories, Inc. (OTC: RTSL) an SEC fully-reporting, growth-oriented aerosol manufacturing and marketing company focused on...
Fresh Farms E-Liquid Confirms September 6 Submission of Highly-Anticipated PMTA
15 sept. 2020 10h04 HE
|
Fresh Farms E-Liquid, LLC
FOUNTAIN VALLEY, Calif., Sept. 15, 2020 (GLOBE NEWSWIRE) -- via NetworkWire -- Fresh Farms E-Liquid, LLC, a global leader in both the vapor and CBD industries, confirmed its September 6, 2020...
Open Book Extracts Acquires Chilmark Labs to Commercialize Rare Cannabinoids and Pioneer Scientific Research and Technologies for the CBD Industry
15 juin 2020 07h00 HE
|
Open Book Extracts
ROXBORO, N.C., June 15, 2020 (GLOBE NEWSWIRE) -- Open Book Extracts, one of the leading vertically integrated, cGMP certified processors of high-quality cannabinoid products, is pleased to announce...
Acquired Sales Corp. Signs Definitive Merger Agreement to Acquire 100% of Rapidly Growing Lifted Liquids
08 janv. 2020 07h00 HE
|
Acquired Sales Corp.
LAKE FOREST, Ill., Jan. 08, 2020 (GLOBE NEWSWIRE) -- Acquired Sales Corp. (OTC Pink: AQSP) today announced that it has signed a definitive merger agreement to acquire 100% of rapidly growing and...
MCTC Expands R&D Program to Include Producing Polymeric Nanoparticles of Valuable, Hard-to-Obtain Cannabinoids
20 nov. 2019 07h30 HE
|
MCTC Holdings Inc. (d/b/a Cannabis Global)
LOS ANGELES, Nov. 20, 2019 (GLOBE NEWSWIRE) -- via NetworkWire – MCTC Holdings Inc. (OTC: MCTC) today announces an expanded R&D program designed to produce polymeric nanoparticles of cannabinol...
Independent Valuation of U.S. Patent Number 9,763,991 for Cannabinol (CBN) Initiated as Cannabis Science Negotiates Licensing and Marketing Deals in Canada and the USA to Develop and Sell CBN Products Utilizing the Company’s Patent
15 avr. 2019 07h33 HE
|
Cannabis Science, Inc.
Cannabis Science’ CBN Patent is for the Treatment of Neurological Conditions, Including Sleep Deprivation, Anxiety, PTSD, and More IRVINE, CA, April 15, 2019 (GLOBE NEWSWIRE) -- via...
Cannabis Science Set to Integrate Its Sponsored Research In Nigeria to Include Its U.S. Patent Number 9,763,991 for Compositions of Cannabinol (CBN) for Treatment of Various Neurological Conditions
25 févr. 2019 07h28 HE
|
Cannabis Science, Inc.
IRVINE, CA, Feb. 25, 2019 (GLOBE NEWSWIRE) -- Pre-Clinical Work and Animal Studies Underway, and Protocols for Clinical Studies Under Development via NEWMEDIAWIRE -- Cannabis Science, Inc....
Axim® Biotechnologies Announces Positive Results From Stability And Dissolution Tests On Medchew Rx Showing Greater Than 90% Availability
07 août 2018 08h55 HE
|
AXIM BIOTECHNOLOGIES, INC
NEW YORK, Aug. 07, 2018 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTC: AXIM), a world leader in cannabinoid research and development, today announced positive results from...
Relevium Creates Biocannabix Subsidiary and Targets Legal Cannabis Business
19 avr. 2018 10h14 HE
|
Relevium Technologies Inc
MONTREAL, April 19, 2018 (GLOBE NEWSWIRE) -- Relevium Technologies Inc. (TSX VENTURE:RLV) (OTCQB:RLLVF) (FRANKFURT:6BX) (the “Company” or “Relevium”), is pleased to announce the creation of...